1888 Press Release - The acquisition will add novel scientific platform and manufacturing expertise to Nano Vivere's research and operational capabilities. Nano Vivere, a late stage clinical company, pioneering nanomedicine whose technology is based on proprietary technologies and patents, today announced that Nano Vivere and global lead in cellular immunotherapy company will sign a definitive merger agreement in which Nano Vivere has agreed to acquire the company.
No comments:
Post a Comment